MedTrace Logo

Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

NCT03576443 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-10-13

No results posted yet for this study

Summary

Based on the high response rate in heavily pretreated patients with indolent B-cell lymphomas, among which it is likely that many have undetected transformed disease, the investigators hypothesize that idelalisib may also be active in relapsed DLBCL, particularly of the GCB subtype. Possibly, the efficacy may be related to the presence of specific mutations within the B-cell receptor pathway.

Conditions

Interventions

DRUG

Idelalisib

Idelalisib 150 mg x 2 p o

Sponsors & Collaborators

  • Nordic Lymphoma Group

    lead NETWORK

Principal Investigators

  • Mats Jerkeman · Department of Oncology Skåne University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-07
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03576443 on ClinicalTrials.gov